ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "registries and rheumatoid arthritis (RA)"

  • Abstract Number: 227 • 2018 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis Patients Treated with Abatacept, Rituximab and Tocilizumab in Denmark and Sweden: Risk of Serious Infections

    Kathrine Lederballe Grøn1, Elizabeth V. Arkema2, Bente Glintborg1, Frank Mehnert3, Mikkel Østergaard4, Lene Dreyer5, Mette Nørgaard3, Niels Steen Krogh6, Johan Askling7 and Merete Lund Hetland8, 1The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, 2Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, 3Aarhus University Hospital, Clinical Epidemiological Department, Aarhus, Denmark, 4The DANBIO registry and the Danish Departments of Rheumatology, Glostrup, Denmark, 5Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University, 9000 Aalborg, Denmark, 6ZiteLab ApS, Copenhagen, Denmark, 7Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, 8DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark

    Background/Purpose: Safety concerns have been raised regarding the risk of serious infections (SI) with the different available biologic disease-modifying anti-rheumatic drugs (bDMARDs). Little is known…
  • Abstract Number: 2857 • 2018 ACR/ARHP Annual Meeting

    An Electronic Audit, Reporting, and Data Correction System Improves the Quantity and Quality of Observational Data Collected for US Veterans Enrolled in the Veterans Affairs Rheumatoid Arthritis Registry

    Grant W. Cannon1,2, Jorge Rogas2, Neill Bell3, Joshua Baker4, Gail S. Kerr5, Angelo Gaffo6, J. Steuart Richards7, Jennifer Barton8, Pascale Schwab8, Ted R. Mikuls9, Namrata Singh10, Liron Caplan11, Deana Lazaro12, Andreas Reimold13 and Brian Sauer2, 1Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 2Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 3Salt Lake City VA Medical Center and University of Utah, Dallas VA Medical Center, Dallas, TX, 4Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, 5Washington VA Medical Center, Georgetown and Howard Universities, Washington, DC, 6Birmingham VA and University of Alabama at Birmingham, Birmingham, AL, 7Pittsburgh VA Medical Center and University of Pittsburgh, Pittsburgh, PA, 8VA Portland Health Care System and Oregon Health and Science, Portland, OR, 9VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 10Internal Medicine, Iowa City VA Medical Center and University of Iowa, Iowa City, IA, 11Div of Rheumatology, Denver VA Medical Center and University of Colorado, Aurora, CO, 12Brooklyn VA Medical Center and SUNY Downstate, Brooklyn, NY, 13Rheumatology, Dallas VA Medical Center and University of Texas - Southwestern, Dallas, TX

    Background/Purpose:   The Veterans Affairs (VA) Rheumatoid Arthritis (RA) (VARA) registry is an observational cohort study of US Veterans with RA at 11 VA Medical…
  • Abstract Number: 541 • 2017 ACR/ARHP Annual Meeting

    Decreasing Trend of Serious Infections Incidence Rate Along Years in Rheumatoid Arthritis Patients Exposed to Biologics. Data from Two Latin America Registries

    Roberto Ranza1, Ieda Maria Magalhães Laurindo2, Georges Christopoulos2, Gimena Gomez3, Enrique R Soriano4, Miguel Angel Descalzo5 and Maria de la Vega6, 1on behalf of the BiobadaBrasil study group, Sociedade Brasileira de Reumatologia, Uberlandia, Brazil, 2on behalf of the BiobadaBrasil study group, Sociedade Brasileira de Reumatologia, São Paulo, Brazil, 3on behalf of BiobadaSar study group, Sociedad Argentina de Reumatologia, Buenos Aires, Argentina, 4Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 5Research Unit, Fundacion piel sana AEDV, Madrid, Spain, Madrid, Spain, 6on behalf of BiobadaSar study group, Sociedad Argentina de Reumatologia, Buenos aires, Argentina

    Background/Purpose: Infections are the most frequent and concerning serious adverse events related to rheumatoid arthritis (RA) treatment with biologic drugs (bDMARDs). Their safety profile might…
  • Abstract Number: 1442 • 2017 ACR/ARHP Annual Meeting

    Corticosteroid Sparing Effect of Non-TNF Targeted Biologics, Rituximab, Abatacept and Tocilizumab in Common Practice: Data from 3183 Patients Enrolled in the French Society of Rheumatology Registries

    Jacques-Eric Gottenberg1, Jacques Morel2, Arnaud Constantin3, Thomas Bardin4, Alain Cantagrel5, Bernard Combe2, Maxime Dougados6, René-Marc Flipo7, Alain Saraux8, Thierry Schaeverbeke9, Jean Sibilia10, Martin Soubrier11, Olivier Vittecoq12,13, Gabriel Baron14, Elodie Perrodeau15, Philippe Ravaud14 and Xavier Mariette16, 1CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France, 2Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, 3Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, 4Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, 5Department of Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, Toulouse, France, 6Rheumatology, Paris Descartes University, Paris, France, 7Rheumatology, Department of Rheumatology, CHU Teaching Hospital Lille, France., Lille, France, 8Rheumatology, Brest University Hospital, Brest, France, 9Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France, 10Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 11Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, 12INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, 13Rheumatology Department and INSERM U 905, CHU Rouen, Rouen, France, 14Hôpital Hôtel Dieu, Paris, France, 15Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 16Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France

    Background/Purpose: Little is known regarding the corticosteroid sparing effect of non-TNF biologics in rheumatoid arthritis (RA). Objectives : To compare the corticosteroid sparing effect of…
  • Abstract Number: 1406 • 2016 ACR/ARHP Annual Meeting

    Towards Harmonized Data Collection in Rheumatoid Arthritis (RA): The EULAR Task Force for Standardizing a Minimum Data Collection for RA Observational Research

    Helga Radner1, Elena Nikiphorou2, Katerina Chatzidionysiou3, Laure Gossec4, Kimme L. Hyrich5, Codruta Zăbălan6, Yvonne JL van Eijk-Hustings7, Paula Williamson8, William G Dixon9, Johan Askling10 and The EULAR Task Force for standardising minimum data collection in Rheumatoid Arthritis observational research, 1Rheumatology, Medical University of Vienna, Vienna, Austria, 2Whittington Hospital, London, United Kingdom, 3Department of Medicine, Unit of Rheumatology, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 4Paris 06 University and AP-HP, Hôpital Pitié Salpêtrière, Paris, France, 5Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 6Romanian League against Rheumatism, BUCHAREST, Romania, 7Patient&Care, Maastricht University Medical Centre, Maastricht, Netherlands, 8Clinical Trials Research Centre, University of Liverpool, Liverpool, United Kingdom, 9Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, Great Britain, 10Dept. of Medicine, Rheumatology Unit & Clinical Epidemiology Unit, Karolinska Institute, Stockholm, Sweden

    Background/Purpose: Collaborative research is compromised by heterogeneity of data collection in observational rheumatoid arthritis (RA) databases. Therefore a EULAR taskforce has been convened to develop…
  • Abstract Number: 2527 • 2016 ACR/ARHP Annual Meeting

    Drug Retention of Biologics in Rheumatoid Arthritis Patients: The Role of Baseline Characteristics and Impact of Time-Varying Factors

    Delphine Courvoisier1, Deshire Alpizar Rodriguez2, Jacques-Eric Gottenberg3, Florenzo Iannone4, Elisabeth Lie5, Maria José Santos6, Karel Pavelka7, Merete Lund Hetland8, Carl Turesson9, Xavier Mariette10, Denis Choquette11 and Axel Finckh12, 1University hospital of Geneva, Geneva, Switzerland, 2Rheumatology, University Hospitals of Geneva, Geneva, Switzerland, 3Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 4Reumatologia Universita e Policlinico di Bari, Bari, Italy, 5Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 6Reumatologia, Hospital Garcia de Orta, Almada, Portugal, 7Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 8Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, 9Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, 10INSERM U1184, Université Paris-Sud, Paris, France, Le Kremlin Bicetre, France, 11Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, 12Rheumatology Division, University Hospital of Geneva, Geneva, Switzerland

    DRUG RETENTION  OF BIOLOGICS IN RHEUMATOID ARTHRITIS PATIENTS: THE ROLE OF BASELINE CHARACTERISTICS AND IMPACT OF TIME-VARYING FACTORS D.S. Courvoisier1, D. Alpizar-Rodriguez1, JE. Gottenberg2, F. Iannone4,…
  • Abstract Number: 427 • 2015 ACR/ARHP Annual Meeting

    The Impact of Biologic Agent Initiation after 1 Versus 2 Prior Csdmards in Patients with Rheumatoid Arthritis

    Dimitrios A. Pappas1,2, Jenny Griffith3, Chitra Karki2, Mei Liu4, Joel M. Kremer5, Arijit Ganguli3 and Jeffrey D. Greenberg2,6, 1Columbia University, New York, NY, 2Corrona, LLC, Southborough, MA, 3AbbVie Inc., North Chicago, IL, 4352 Turnpike Rd, Corrona, LLC, Southborough, MA, 5Albany Medical College and The Center for Rheumatology, Albany, NY, 6NYU School of Medicine, New York, NY

    Background/Purpose: Patients with Rheumatoid Arthritis (RA) who don’t respond to conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) should be treated with biologic agents(1). The objective…
  • Abstract Number: 2521 • 2015 ACR/ARHP Annual Meeting

    Pregnancies in Patients with Long-Standing Rheumatoid Arthritis and Biologic DMARD Treatment: Course of Disease during Pregnancy and Pregnancy Outcomes

    Anja Strangfeld1, Dagmar Pattloch1, Madlen Spilka2, Bernhard Manger3, Brigitte Krummel-Lorenz4, Annett Gräßler5, Joachim Listing6 and Angela Zink1,7, 1Epidemiology, German Rheumatism Research Center, Berlin, Germany, 2German Rheumatism Research Center, Berlin, Germany, 3Rheumatologist, Scientific Advisory Board, Erlangen, Germany, 4Rheumatologist, Frankfurt, Germany, 5Rheumatologist, Pirna, Germany, 6Epidemiologiy, German Rheumatism Research Center, Berlin, Germany, 7Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany

    Background/Purpose: The assumption of spontaneous remission among pregnant women with rheumatoid arthritis (RA) is common. Nevertheless, prospectively collected data describing the course of disease activity…
  • Abstract Number: 2525 • 2014 ACR/ARHP Annual Meeting

    Infliximab Versus Conventional Combination Treatment and Work Loss in Early RA over 7 Years: A Randomized Trial

    Jonas K Eriksson1, Heather Miller2, Johan A Karlsson3, Ingemar F Petersson4, Sofia Ernestam5, Pierre Geborek3, Ronald F van Vollenhoven2 and Martin Neovius1, 1Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 2ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 3Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, 4Section of Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, 5Department of Learning, Informatics and Medical Education (LIME), Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: The introduction of TNF inhibitors has improved the treatment of RA, but at a substantial cost. The randomized Swefot trial compared the addition of…
  • Abstract Number: 2367 • 2014 ACR/ARHP Annual Meeting

    Physician Awareness of Suboptimal Patient Adherence to MTX: Results from a Large U.S. Rheumatoid Arthritis Registry

    Jeffrey R. Curtis1, Aseem Bharat2, Lang Chen3, Jeffrey D. Greenberg4, Joel M. Kremer5 and Dimitrios A. Pappas4, 1Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Medicine, University of Alabama at Birmingham, Birmingham, AL, 4Corrona, LLC., Southborough, MA, 5Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY

    Background/Purpose: Most rheumatoid arthritis (RA) registries capture information about medication use using data captured at office visits. The extent to which this information may be…
  • Abstract Number: 1071 • 2014 ACR/ARHP Annual Meeting

    What Is the Impact of Chronic Systemic Inflammation Such As Rheumatoid Arthritis on Mortality Following Cancer?

    Julia Simard1,2, Sara Ekberg3, Anna Johansson4 and Johan Askling2,5, 1Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, 2Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 3Dept of Medical Epidemiology of Biostatistic, Karolinska Institutet, Stockholm, Sweden, 4Dept of Medical Epidemiology and Biostatistics, Karolinska Institutet, stockholm, Sweden, 5Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose:   Emerging evidence links inflammation and immune-competence to cancer progression and outcome. The few studies addressing cancer survival in the context of systemic inflammation,…
  • Abstract Number: 109 • 2013 ACR/ARHP Annual Meeting

    Comparison Of Characteristics In Rheumatoid Arthritis Between International and National Databases In Europe: A Systematic Literature Review

    E. Gvozdenovic1, R. Koevoets1, J. Langenhoff2, C.F. Allaart1 and R. Landewe3, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands, 3Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands

    Background/Purpose: RA (Rheumatoid Arthritis) cohorts and registers are established for daily practice in clinical care. There are still differences between registries in disease activity and…
  • Abstract Number: 2910 • 2013 ACR/ARHP Annual Meeting

    Differences In Abatacept Use In Rheumatoid Arthritis Patients Across Europe: A Pan-European Database Analysis Of Abatacept In European RA Registries

    David Neto1, Axel Finckh2, Florenzo Iannone3, Estíbaliz Loza4, Elisabeth Lie5, Piet L.C. Van Riel6, Merete L. Hetland7, Karel Pavelka8, Jacques-Eric Gottenberg9, Xavier Mariette10 and Carl Turesson11, 1University of Geneva, Geneva, Switzerland, 2Rheumatology, Geneva University Hospital, Geneva, Switzerland, 3D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy, 4Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 5Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 6Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 7Copenhagen University Hospital Glostrup, Copenhagen, Denmark, 8Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, 9Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, 10Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, 11Department of Rheumatology, Skåne University Hospital, Malmö, Sweden

    Background/Purpose: Several European registries have pooled data of patients (pts) who received Abatacept (ABA) for rheumatoid arthritis (RA) to acquire new knowledge about performance of…
  • Abstract Number: 1514 • 2013 ACR/ARHP Annual Meeting

    Drug Survival In Patients Receiving Golimumab Treatment 2010-2013. Results From The Swedish Rheumatology Quality Register

    Saedis Saevarsdottir1, Michele Santacatterina2, Leszek Stawiarz3, Carl Turesson4, Helena Forsblad5, Lennart T.H. Jacobsson6 and Staffan Lindblad7, 1Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, 2Biostatistics Core Facility, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 3Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, 4Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 5Dept of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 6Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 7Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)…
  • Abstract Number: 1483 • 2013 ACR/ARHP Annual Meeting

    Physician and Patient Characteristics Associated With The Decision To Treat Rheumatoid Arthritis Patients With Biologic Monotherapy In Usual Care Settings

    Mariely Nieves-Plaza1, Heather Eng2, Ilinca D. Metes3, Ashwini Shewede4, Stephen R. Wisniewski2, Ani John4 and Marc C. Levesque5, 1Clinical And Translational Science Institute, Univeristy of Pittsburgh, Pittsburgh, PA, 2Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, 3Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, 4Genentech Inc., South San Francisco, CA, 5Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA

    Background/Purpose: Approximately 30% of rheumatoid arthritis (RA) patients treated with a biologic, receive the biologic as monotherapy i.e. without concomitant oral disease modifying anti-rheumatic drugs…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology